Recent cardiovascular outcome trials (CVOTs) have provided evidence that the Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a promising hypoglycemic drug that can delay the progression of atherosclerosis (1, 2) and improve the prognosis of ASCVD patients (3–5). The gene discussed is GLP1R; the disease is atherosclerosis.